Sign in

You're signed outSign in or to get full access.

Michael Hoer

Director at MEDIFASTMEDIFAST
Board

About Michael A. Hoer

Independent director at Medifast since 2018; age 70; serves on the Audit and Compensation Committees and is designated an Audit Committee Financial Expert. Former Controller, CFO, and President with extensive Asia operating experience; education includes a BA in Chinese and an MBA from Brigham Young University .

Past Roles

OrganizationRoleTenureCommittees/Impact
Continental Grain CompanyPresident — Continental Enterprises Ltd. & Managing Director — Conti Asia; prior roles of increasing responsibility1992–2007Led Asia operations; finance and leadership credentials highlighted for Audit/Comp roles
Beijing H-Hova Purification Technology Co. Ltd.DirectorAug 2012–Jul 2016Industrial JV board oversight in China
Dynasty Petroleum Holdings LLCChairmanNot disclosedEnergy sector governance experience
First Western AdvisorsDirectorNot disclosedFinancial services board role
Avantar LLCDirectorNot disclosedTechnology/marketing data board role
Humanitarian projects (Egypt and Sudan)Volunteer project managerSince 2018Social impact and governance perspective

External Roles

OrganizationRoleTenureNotes
Taiwan Fu Hsing Industrial Co. Ltd.DirectorCurrentExternal public/industrial board; potential supply chain perspective
Brigham Young UniversityNational Advisory Council memberCurrentAcademic advisory governance experience

Board Governance

  • Independence: Board determined Hoer is independent under NYSE rules; he is also “non-employee” for Exchange Act purposes on Compensation Committee .
  • Committees: Audit Committee member and Compensation Committee member; designated Audit Committee Financial Expert .
  • Attendance and engagement: 100% attendance at Board and committee meetings in 2024; directors expected to attend the annual meeting, and all incumbents did in 2024 .
  • Board activity levels (2024): Board met 4 times; Audit 4; Compensation 8; Nominating/Governance 4; Executive 4 .
Governance AttributeStatus
IndependenceIndependent director
Lead/Chair rolesNot a chair; Audit Chair is Brown; Compensation Chair is Schlackman
Audit Financial ExpertYes (“+” designation)
Attendance (2024)100% Board/committee attendance
Director since2018

Fixed Compensation

ComponentAmountNotes
Fees Earned (Cash)$82,5002024 director cash fees
Annual RetainerQuarterly $16,250Standard program; lead director receives an additional $6,250 per quarter (not applicable to Hoer)
Committee Meeting Fees$1,250–$5,000 per meetingPaid by committee and role; electable in shares

Performance Compensation

Equity ComponentGrant/ValueVestingElections/Plan
Stock Awards (RSUs)$135,614 (grant-date fair value)2024 RSUs granted at the June 2024 Board meeting; scheduled to vest on June 20, 2025Non-employee directors can defer equity to the Director Deferred Compensation Plan (DCP), with a 15% premium on deferred equity; in 2024, all non-employee directors deferred 100% of equity compensation (aside from Xian and Brown, who deferred 100% of total compensation)
Outstanding RSUs (as of 12/31/2024)11,841 unitsPer DCP; RSUs creditedOutstanding awards summary
OptionsNone granted in 2024N/ACompany did not issue options/SARs in 2024

No performance metrics are tied to director equity awards; RSUs are time-based. The company prohibits repricing of stock options in its plan and did not time grants around material nonpublic information .

Other Directorships & Interlocks

Company/InstitutionRoleInterlock/Conflict with MED
Taiwan Fu Hsing Industrial Co. Ltd.DirectorNone disclosed
Brigham Young University (National Advisory Council)MemberNone disclosed
Compensation Committee InterlocksN/ACompany discloses no interlocks; Hoer served on Comp Committee alongside Schlackman and Thomas; no reciprocal executive overlaps reported

Expertise & Qualifications

  • Finance and leadership pedigree (former Controller, CFO, and President), extensive international operating experience in Asia; designated Audit Committee Financial Expert, supporting financial reporting oversight .
  • Education: BA in Chinese; MBA from Brigham Young University .

Equity Ownership

MetricValue
Beneficial Ownership (shares)14,971
% of Shares Outstanding<1% (asterisk denotes less than 1%)
Outstanding RSUs (DCP credited)11,841
Stock Ownership GuidelinesNon-employee directors: 5x annual cash retainer; must hold at least 50% of shares acquired until compliant
Hedging/PledgingProhibited for officers and directors
Section 16(a) ReportingCompany concluded all reports timely filed for FY2024

Governance Assessment

  • Strengths: Independent director; Audit Committee Financial Expert; dual committee service (Audit, Compensation); 100% attendance; robust anti-hedging/anti-pledging posture; director stock ownership guidelines enhance alignment .
  • Alignment: Equity grants and DCP with 15% premium encourage longer horizons and ownership accumulation; ability to elect equity in lieu of cash (and deferral) signals potential alignment, though the premium may be viewed as generous in down markets .
  • Potential conflicts/related-party exposure: None disclosed for Hoer; Audit Committee oversees related-party transaction process; no Section 16(a) deficiencies reported .
  • Watch items: Beneficial ownership is modest (<1%), typical for small-cap boards but offers limited “skin-in-the-game”; ensure continued focus on risk oversight given industry transformation and committee workloads (8 Compensation meetings in 2024) .

Overall signal: Board effectiveness supported by financial expertise and strong attendance; compensation structure and ownership policies are shareholder-friendly (no hedging/pledging, equity-based director pay). No disclosed conflicts or interlocks involving Hoer; alignment is adequate but not deeply ownership-heavy .